Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLMW NASDAQ:CYCCP NASDAQ:DRTSW NASDAQ:SXTPW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.01-10.3%$0.01$0.00▼$0.05N/AN/A27,433 shs45,811 shsCYCCPCyclacel Pharmaceuticals$5.05$5.64$3.45▼$7.40N/AN/A5,160 shsN/ADRTSWAlpha Tau Medical$1.89-3.1%$1.65$0.20▼$2.99N/AN/A54,109 shs12,759 shsSXTPW60 Degrees Pharmaceuticals$0.04-7.1%$0.05$0.03▼$0.16N/AN/A11,566 shs5,683 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-10.34%+19.27%+2.36%-2.99%-12.75%CYCCPCyclacel Pharmaceuticals0.00%0.00%0.00%0.00%-7.34%DRTSWAlpha Tau Medical-3.77%+5.00%-12.09%+89.00%+700.85%SXTPW60 Degrees Pharmaceuticals-7.07%-8.97%-11.47%-62.55%-31.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMWApollomics$0.01-10.3%$0.01$0.00▼$0.05N/AN/A27,433 shs45,811 shsCYCCPCyclacel Pharmaceuticals$5.05$5.64$3.45▼$7.40N/AN/A5,160 shsN/ADRTSWAlpha Tau Medical$1.89-3.1%$1.65$0.20▼$2.99N/AN/A54,109 shs12,759 shsSXTPW60 Degrees Pharmaceuticals$0.04-7.1%$0.05$0.03▼$0.16N/AN/A11,566 shs5,683 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMWApollomics-10.34%+19.27%+2.36%-2.99%-12.75%CYCCPCyclacel Pharmaceuticals0.00%0.00%0.00%0.00%-7.34%DRTSWAlpha Tau Medical-3.77%+5.00%-12.09%+89.00%+700.85%SXTPW60 Degrees Pharmaceuticals-7.07%-8.97%-11.47%-62.55%-31.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMWApollomics 0.00N/AN/AN/ACYCCPCyclacel Pharmaceuticals 0.00N/AN/AN/ADRTSWAlpha Tau Medical 0.00N/AN/AN/ASXTPW60 Degrees Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMWApollomics$8.50MN/AN/AN/AN/AN/ACYCCPCyclacel PharmaceuticalsN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/ASXTPW60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMWApollomicsN/AN/AN/AN/AN/AN/AN/AN/AN/ACYCCPCyclacel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)SXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMWApollomicsN/AN/AN/AN/AN/ACYCCPCyclacel Pharmaceuticals$0.6011.88%N/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/ASXTPW60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMWApollomicsN/ACYCCPCyclacel PharmaceuticalsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPLMWApollomicsN/ACYCCPCyclacel PharmaceuticalsN/ADRTSWAlpha Tau MedicalN/ASXTPW60 Degrees PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMWApollomics59N/AN/ANot OptionableCYCCPCyclacel Pharmaceuticals12N/AN/ANot OptionableDRTSWAlpha Tau Medical80N/AN/ANot OptionableSXTPW60 Degrees Pharmaceuticals2N/AN/ANot OptionableCYCCP, SXTPW, DRTSW, and APLMW HeadlinesRecent News About These Companies60 Degrees details tafenoquine priority review voucher strategyJune 3, 2026 | tipranks.com60 Degrees Pharmaceuticals, Inc. Partners with Runway Health to Offer ARAKODA® for Convenient Online Malaria PreventionApril 15, 2026 | quiverquant.comQ60 Degrees Pharmaceuticals Reports 65% Increase in FY 2025 Net Product Revenues to $1.0 Million and Operational DevelopmentsMarch 31, 2026 | quiverquant.comQ60 Degrees Updates Affiliate Share Ownership Disclosure ErrorMarch 20, 2026 | tipranks.com60 Degrees Pharmaceuticals Updates Legal Opinion for ATM OfferingMarch 13, 2026 | tipranks.com60 Degrees Pharmaceuticals Regains Nasdaq Listing Compliance StatusFebruary 12, 2026 | tipranks.comGoodRx Partners with 60 Degrees Pharmaceuticals to Offer Up to 30% Savings on ARAKODA® for Malaria PreventionFebruary 2, 2026 | quiverquant.comQ60 Degrees Pharmaceuticals Faces Immediate Nasdaq Delisting AppealJanuary 23, 2026 | tipranks.com60 Degrees Pharmaceuticals Implements One-for-Four Reverse SplitJanuary 21, 2026 | tipranks.com60 Degrees Pharma outlines growth strategy in investor webinarJanuary 8, 2026 | tipranks.com60 Degrees Pharmaceuticals, Inc. Confirms Continuation of B-FREE Study to Assess ARAKODA® for Chronic Babesiosis TreatmentDecember 29, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Plans Expansion of Sales and Marketing Initiatives Following Positive Clinical Pilot ResultsDecember 11, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Launches First-Ever Study for Tafenoquine in Chronic Babesiosis PatientsNovember 21, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth EffortsNovember 17, 2025 | tipranks.com60 Degrees Pharmaceuticals, Inc. Reports 223% Increase in Q3 2025 Net Product Revenue Despite Gross LossNovember 13, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic BabesiosisOctober 27, 2025 | tipranks.com60 Degrees Pharmaceuticals Submits Breakthrough Therapy Designation Request to FDA for Tafenoquine in Treating Relapsing BabesiosisOctober 15, 2025 | quiverquant.comQ60 Degrees Pharmaceuticals unveils name of chronic babesiosis trialOctober 9, 2025 | msn.com60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis StudyOctober 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Launches B-FREE Chronic Babesiosis Study Following Patient Naming Competition and $5K Charity DonationOctober 9, 2025 | quiverquant.comQMedia Sentiment Over TimeCYCCP, SXTPW, DRTSW, and APLMW Company DescriptionsApollomics NASDAQ:APLMW$0.01 0.00 (-10.34%) As of 06/16/2026 12:37 PM EasternApollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.Cyclacel Pharmaceuticals NASDAQ:CYCCPCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise Sapacitabine, an orally available prodrug of CNDAC, which is a novel nucleoside analog. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.Alpha Tau Medical NASDAQ:DRTSW$1.89 -0.06 (-3.08%) As of 06/16/2026 03:51 PM Eastern This is a fair market value price provided by Massive. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTPW$0.04 0.00 (-7.07%) As of 06/16/2026 03:56 PM Eastern60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
